L
Lyell Immunopharma D
D
LYEL
0.93030
USD
0.00
(0.38%)
Market Closed
Volume
6,626
EPS
-1
Div Yield
-
P/E
-1
Market Cap
259,758,937
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: Lyell Immunopharma
Sector: Healthcare
Industry: Biotechnology
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.